On Apr. 28, 2020, INOVIO announced that its Phase 1 U.S. clinical trial for COVID-19 DNA vaccine INO-4800 was fully enrolled with all 40 healthy volunteers receiving their first dose, with interim immune responses and safety results expected in late June.

The 40 healthy volunteers enrolled at sites at the University of Pennsylvania in Philadelphia, PA, and a clinic in Kansas City, MO, received two doses of INO-4800 four weeks apart. The Phase 1 study was designed to assess the safety profile and immunogenicity of INO-4800 in support of advancing rapidly to a Phase 2/3 efficacy trial, which was planned to potentially initiate in the summer.